Vivos Therapeutics, Inc.
VVOS
$2.12
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 77.57% | 26.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 77.57% | 26.66% | |||
| Cost of Revenue | 66.43% | 13.47% | |||
| Gross Profit | 86.59% | 39.83% | |||
| SG&A Expenses | 24.26% | 27.03% | |||
| Depreciation & Amortization | 25.49% | 72.88% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.61% | 25.25% | |||
| Operating Income | 2.69% | -24.17% | |||
| Income Before Tax | -7.72% | -29.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.72% | -29.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.72% | -29.74% | |||
| EBIT | 2.69% | -24.17% | |||
| EBITDA | 4.58% | -21.87% | |||
| EPS Basic | 10.73% | -22.74% | |||
| Normalized Basic EPS | 10.73% | -22.70% | |||
| EPS Diluted | 10.73% | -22.74% | |||
| Normalized Diluted EPS | 10.73% | -22.70% | |||
| Average Basic Shares Outstanding | 20.65% | 5.72% | |||
| Average Diluted Shares Outstanding | 20.65% | 5.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||